Document and Entity Information - USD ($) $ in Millions |
12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2024 |
Mar. 13, 2025 |
Jun. 28, 2024 |
|
| Cover [Abstract] | |||
| Document Type | 10-K | ||
| Document Annual Report | true | ||
| Document Transition Report | false | ||
| Document Period End Date | Dec. 31, 2024 | ||
| Entity File Number | 001-39712 | ||
| Entity Registrant Name | OLEMA PHARMACEUTICALS, INC. | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Tax Identification Number | 30-0409740 | ||
| Entity Address, Address Line One | 780 Brannan Street | ||
| Entity Address, City or Town | San Francisco | ||
| Entity Address, State or Province | CA | ||
| Entity Address, Postal Zip Code | 94103 | ||
| City Area Code | 415 | ||
| Local Phone Number | 651-3316 | ||
| Title of 12(b) Security | Common Stock | ||
| Trading Symbol | OLMA | ||
| Security Exchange Name | NASDAQ | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Interactive Data Current | Yes | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | false | ||
| Entity Shell Company | false | ||
| Entity Public Float | $ 454.3 | ||
| ICFR Auditor Attestation Flag | false | ||
| Document Financial Statement Error Correction [Flag] | false | ||
| Entity Common Stock, Shares Outstanding | 68,333,065 | ||
| Auditor Name | Ernst & Young LLP | ||
| Auditor Firm ID | 42 | ||
| Auditor Location | Iselin, New Jersey | ||
| Entity Central Index Key | 0001750284 | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Fiscal Year Focus | 2024 | ||
| Document Fiscal Period Focus | FY | ||
| Amendment Flag | false | ||
| Documents Incorporated by Reference [Text Block] | DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive Proxy Statement for the 2024 Annual Meeting of Stockholders to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10‑K are incorporated by reference in Part III, Items 10‑14 of this Annual Report on Form 10‑K. |
||
| Opinion on the Financial Statements | Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Olema Pharmaceuticals, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. |